Interferon beta-1a: Clinical Trials

34 trials of Interferon beta-1a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 4 withdrawn, 3 terminated, 1 active not recruiting. 34 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 434Completed 25, Withdrawn 4, Terminated 3, Active not recruiting 1, Unknown 1

Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interferon Beta 1a in Hospitalized COVID-19 Patients
Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19
Phase 4UnknownShahid Beheshti University of Medical Sciences402020-04-152020-04-20
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting
Phase 4Active not recruitingThe Cleveland Clinic8002019-01-032026-08-31
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedBiogen802017-01-302020-11-25
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Rebif - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Phase 4CompletedMerck KGaA, Darmstadt, Germany1062014-12-312018-03-30
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
Interferon Beta, BIIB017 (Peginterferon beta-1a) - Relapsing Multiple Sclerosis
Phase 4WithdrawnBiogen2014-10-012014-11-17
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
Rebif® - Multiple Sclerosis
Phase 4TerminatedEMD Serono12014-06-012017-01-23
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
Rebif® - Multiple Sclerosis, Relapsing-Remitting
Phase 4CompletedMerck KGaA, Darmstadt, Germany2002014-05-312018-09-20
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
Rebif® - Multiple Sclerosis, Relapsing-Remitting
Phase 4CompletedMerck KGaA, Darmstadt, Germany932013-02-282017-08-24
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals2982012-01-012014-08-08
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals612011-05-012015-06-22
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Fingolimod, Standard MS DMTs - Relapsing Forms of Multiple Sclerosis
Phase 4CompletedNovartis Pharmaceuticals10532010-08-012014-02-10
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
Rebif - Multiple Sclerosis
Phase 4CompletedEMD Serono382010-06-302018-02-23
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
TYSABRI and AVONEX - Relapsing-remitting Multiple Sclerosis
Phase 4WithdrawnBiogen2008-11-012024-06-03
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Interferon beta-1a - Relapsing Remitting Multiple Sclerosis
Phase 4TerminatedBiogen192007-06-012008-09-04
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Betaferon/Betaseron, Rebif - Relapsing-remitting Multiple Sclerosis
Phase 4CompletedBayer2202006-03-012013-10-21
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
Interferon-beta-1a, Simvastatin, Placebo - Multiple Sclerosis
Phase 4CompletedBiogen3802006-02-012010-10-15
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Interferon beta-1a (Rebif) - Multiple Sclerosis, Relapsing-Remitting
Phase 4CompletedMerck KGaA, Darmstadt, Germany302005-12-012014-02-27
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
Interferon beta-1a - Multiple Sclerosis, Relapsing, Remitting
Phase 4CompletedMerck KGaA, Darmstadt, Germany792005-01-012013-12-27
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
Rebif - Relapsing-Remitting Multiple Sclerosis
Phase 4WithdrawnEMD Serono2004-11-012013-08-06
EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis
Avonex/Zocor - Multiple Sclerosis
Phase 4CompletedUniversity of North Carolina302004-09-012008-03-05

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Multiple Sclerosis (19)  ·  Multiple Sclerosis, Relapsing-Remitting (18)  ·  Optic Neuritis (2)  ·  COVID-19 (1)  ·  Cerebellar Diseases (1)  ·  Demyelinating Diseases (1)  ·  Myelitis (1)  ·  Myelitis, Transverse (1)  ·  Neuritis (1)  ·  Recurrence (1)

Sponsors

Biogen (12)  ·  Merck KGaA, Darmstadt, Germany (6)  ·  EMD Serono (4)  ·  Novartis Pharmaceuticals (3)  ·  MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute (2)  ·  Bayer (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Louisiana State University Health Sciences Center Shreveport (1)  ·  Shahid Beheshti University of Medical Sciences (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)  ·  The Cleveland Clinic (1)  ·  University of North Carolina (1)

Countries

United States (9)  ·  Germany (4)  ·  United Kingdom (4)  ·  Sweden (3)  ·  Australia (2)  ·  Belgium (2)  ·  Canada (2)  ·  Denmark (2)  ·  Finland (2)  ·  France (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Russia (2)  ·  Switzerland (2)  ·  Argentina (1)

Top investigators

Alireza Minagar, MD (1)  ·  Bettina Stubinski, M.D. (1)  ·  Bruno Brochet, MD, Prof. (1)  ·  Daniel Ontaneda, MD, MSc (1)  ·  Fernando Dangond, MD (1)  ·  Helene Brooks (1)  ·  Ilad Alavi Darazam, MD (1)  ·  Minoosh Shabani, MD (1)  ·  Mohammadreza Haji Esmaelie, MD (1)

Results publications

PMID 18071030, PMID 18789766, PMID 20542736, PMID 21742556, PMID 23647445, PMID 24625687, PMID 25424122, PMID 26265273, PMID 26265274, PMID 26559139, PMID 31276502, PMID 42218617

NIH funding

2005 (1), 2014 (1), 2016 (1)